作者
Hans J Hammers, Elizabeth R Plimack, Jeffrey R Infante, Brian I Rini, David F McDermott, Lionel D Lewis, Martin H Voss, Padmanee Sharma, Sumanta K Pal, Albiruni R Abdul Razak, Christian Kollmannsberger, Daniel YC Heng, Jennifer Spratlin, M Brent McHenry, Asim Amin
发表日期
2017/12/12
期刊
Journal of Clinical Oncology
卷号
35
期号
34
页码范围
3851
出版商
American Society of Clinical Oncology
简介
Purpose
Combination treatment with immune checkpoint inhibitors has shown enhanced antitumor activity compared with monotherapy in tumor types such as melanoma. The open-label, parallel-cohort, dose-escalation, phase I CheckMate 016 study evaluated the efficacy and safety of nivolumab plus ipilimumab in combination, and nivolumab plus a tyrosine kinase inhibitor in metastatic renal cell carcinoma (mRCC). Safety and efficacy results from the nivolumab plus ipilimumab arms of the study are presented.
学术搜索中的文章
HJ Hammers, ER Plimack, JR Infante, BI Rini… - Journal of Clinical Oncology, 2017